# iFAST Diagnostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ifast-diagnostics

- Industry: Healthcare
- Headquarters: Hampshire, UK
- Website: www.ifastdiagnostics.com/
- Total disclosed funding: $6.7M
- Latest round: Seed (Sep 30, 2024)
- Investors on record: 7

## About

Based in Hampshire, UK, and founded in 2022, iFAST Diagnostics Limited operates as a provider of rapid antimicrobial susceptibility testing (AST) solutions to healthcare facilities, aiming to prevent antimicrobial resistance by delivering better diagnostic results. In November 2024, iFast Diagnostics Limited raised GBP 5 million in seed funding led by KHP Ventures, with participation from QantX, UK Innovation & Science Seed Fund, and Kadmos Capital, Eink, Raw Ventures, and OKG Capital. As of 2024, the company is led by its CEO, Dr. Toby King.

iFAST Diagnostics specializes in antimicrobial susceptibility testing (AST) with its flagship product, the iFAST demonstrator platform. This advanced technology accelerates the testing process, delivering results in under three hours from a positive blood or raw urine sample. The core functionality involves extracting bacteria from the sample, exposing them to various antibiotics, and then using a high-speed microfluidic chip to measure the electrical properties of individual bacteria. This method allows the iFAST reader to determine the optimum antibiotic for treatment, which can take 48 to 72 hours. The company primarily serves hospitals and healthcare facilities across the United Kingdom and is expanding its reach internationally.

iFAST Diagnostics operates on a transaction structure that incorporates direct sales of its testing platforms and associated services to healthcare providers. The pricing for their services is structured at approximately GBP 20 per patient.

The company will use the funding to bring its rapid antimicrobial susceptibility testing platform to market in the United Kingdom, with plans for launches in the US and other European regions.

## Funding rounds

- Seed, Sep 30, 2024, $6.7M — UK Innovation & Science Seed Fund, Meridian Health Ventures, Kadmos Capital, QantX, Raw Ventures, OKG Capital, Eink

## Investors

- UK Innovation & Science Seed Fund (https://capitalatlas.ai/funds/uk-innovation-science-seed-fund) — Seed
- Meridian Health Ventures (https://capitalatlas.ai/funds/meridian-health-ventures) — Seed
- Kadmos Capital (https://capitalatlas.ai/funds/kadmos-capital) — Seed
- QantX (https://capitalatlas.ai/funds/qantx) — Seed
- Raw Ventures (https://capitalatlas.ai/funds/raw-ventures) — Seed
- OKG Capital (https://capitalatlas.ai/funds/okg-capital) — Seed
- Eink — Seed